CAR-T cell therapies have shown great success in treating hematological cancers, including leukemia, lymphoma and multiple myeloma, by using genetically modified T cells to effectively attack cancer. However, as these therapies continue to transform cancer treatment, barriers to access remain a significant challenge. They often stay out of reach for many patients due to their high costs and the time-intensive, centralized manufacturing process. To make them more accessible, the industry is moving toward decentralized CAR-T cell manufacturing. This approach enables hospitals to produce CAR-T cells on-site, reducing the time from months to just days.
Paving the way for more scalable, efficient manufacturing
Dr. Liping Yu, our VP of Applications, sheds light on these challenges and innovative solutions in her latest article published in Drug Discovery World. The publication highlights innovations like automated, column-free cell separation leading the way to simplifying CAR-T production and significantly cutting costs. These advanced technologies preserve cell quality, streamline workflows, and pave the way for more scalable, efficient manufacturing.
At the heart of these developments is the goal to bring CAR-T therapies closer to patients, making treatment faster, more affordable, and widely available. At Applied Cells we are proud to be part of this movement. We leverage MARS platform to support cutting-edge, point-of-care manufacturing solutions.
Automating production within a closed system
Our innovative cell manufacture platform, MARS® Atlas is an advanced, end-to-end solution designed to revolutionize CAR-T cell manufacturing by automating production within a closed system. It addresses key challenges in traditional CAR-T manufacturing, driving progress toward a future where personalized cancer care is more efficient, cost-effective, and within reach for a broader patient population. Learn more about MARS Atlas and join the early access program here.
Let’s continue pushing the boundaries of cell therapy innovation to ensure more patients can benefit from these groundbreaking treatments.
Read the original article: Link here
